I am a physician scientist and I work on the development of new strategies to overcome resistance to hormonal therapy in ER+HER2- metastatic breast cancer. Most recently, we have found a target for metformin in breast cancer and developed a chemical probe for metformin action, hexyl-benzyl-biguanide (HBB), which is 200-fold more potent. Cell Chem Biol. 2017 Oct 19;24(10):1259-1275. My institution is the Masonic Cancer Center, University of Minnesota; Division of Hematology, Oncology, and Transplantation, University of Minnesota. My degrees are S.B. (MIT), M.D., Ph.D. (Johns Hopkins).